SCHEMBL697737

SCHEMBL697737

O=C(CC(O)C(=O)OC(=O)c1ccccc1)OC(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
MAPK1 P28482 1/20 0.49
HIF1A Q16665 1/20 0.49
TDP1 Q9NUW8 2/20 0.46
KMT2A Q03164 4/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
LMNA P02545 2/20 0.44
F2 P00734 1/20 0.44
PRKCA P17252 1/20 0.42
ADRB2 P07550 2/20 0.42
ADRB1 P08588 2/20 0.42
ADRB3 P13945 2/20 0.42
TSHR P16473 3/20 0.42
TP53 P04637 1/20 0.42
CTSG P08311 1/20 0.39
CTRB1 P17538 1/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL697738 0.88 ALDH1A1 (0.53) ALDH1A1MAPK1HIF1ATDP1KMT2A
SCHEMBL11864466 0.88 ALDH1A1 (0.49) ALDH1A1MAPK1HIF1ATDP1KMT2A
SCHEMBL28059255 0.86 ALDH1A1 (0.51) ALDH1A1MAPK1HIF1ATDP1KMT2A
SCHEMBL696395 0.83 ALDH1A1 (0.41) ALDH1A1KMT2ALMNATSHRMEN1
SCHEMBL3390 0.82 ALDH1A1 (0.55) ALDH1A1MAPK1HIF1ATDP1KMT2A
SCHEMBL810936 0.82 KMT2A (0.50) ALDH1A1MAPK1TDP1KMT2ALMNA
SCHEMBL21081464 0.81 MAPK1 (0.47) ALDH1A1MAPK1HIF1ATDP1KMT2A
SCHEMBL3515543 0.81 ALDH1A1 (0.41) ALDH1A1MAPK1HIF1ATDP1KMT2A
SCHEMBL28380754 0.81 ALDH1A1 (0.49) ALDH1A1MAPK1HIF1ATDP1KMT2A
SCHEMBL29009213 0.79 NPC1 (0.51) ALDH1A1MAPK1HIF1ATDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111333561-B Synthetic method of ralotinib intermediate (2R) -2- (2, 5-difluorophenyl) pyrrolidine 安徽德信佳生物医药有限公司 2020-11-27 CN disclosed
CN-111333561-A Synthetic method of ralotinib intermediate (2R) -2- (2, 5-difluorophenyl) pyrrolidine 安徽德信佳生物医药有限公司 2020-06-26 CN disclosed
EP-2423211-B1 PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF KANEKA CORP (JP) 2014-04-16 EP disclosed
EP-2423211-A1 PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF Kaneka Corporation (JP) 2012-02-29 EP disclosed
EP-0783306-A4 METHOD FOR IMPROVING REPRODUCTIVE EFFICIENCY IN FARM ANIMALS MERCK & CO INC (US) 1998-09-23 EP disclosed
EP-0783306-A1 METHOD FOR IMPROVING REPRODUCTIVE EFFICIENCY IN FARM ANIMALS MERCK & CO. INC. (US) 1997-07-16 EP disclosed
WO-1996009824-A1 METHOD FOR IMPROVING REPRODUCTIVE EFFICIENCY IN FARM ANIMALS MERCK & CO., INC. (US) 1996-04-04 WO disclosed
WO-1996008239-A1 USE OF 5-ALPHA-REDUCTASE INHIBITORS TO INCREASE HDL CHOLESTEROL LEVELS MERCK & CO., INC. (US) 1996-03-21 WO disclosed
EP-0663827-A4 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS. MERCK & CO INC (US) 1995-11-15 EP disclosed
EP-0679084-A4 1995-11-08 EP disclosed
WO-1995002607-A1 7-SUBSTITUTED-Δ4-6-AZASTEROID DERIVATIVES AS 5α-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1995-01-26 WO disclosed
WO-1995002587-A1 SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS MERCK & CO., INC. (US) 1995-01-26 WO disclosed
WO-1994021614-A1 SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1994-09-29 WO disclosed
WO-1994014438-A1 HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS MERCK & CO., INC. (US) 1994-07-07 WO disclosed
WO-1994007496-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1994-04-14 WO disclosed
WO-1993006092-A1 PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS MERCK & CO., INC. (US) 1993-04-01 WO disclosed
CN-1070399-A The amide derivatives oxytocin antagonist that piperizinylcamphorsuoxytocin replaces MERCK & CO INC (US) 1993-03-31 CN disclosed
US-5137904-A Useful in the treatment of atherosclerosis and thrombosis G. D. SEARLE & CO. (US) 1992-08-11 US disclosed
EP-0486280-A2 Piperidinylcamphorsulfonyl oxytocin antagonists MERCK & CO. INC. (US) 1992-05-20 EP disclosed
WO-1992007821-A1 DIASTEREOISOMERS OF BICYCLO-SUBSTITUTED PHENYLACETONITRILE DERIVATIVES G.D. SEARLE & CO. (US) 1992-05-14 WO disclosed